Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.
- 12 September 1995
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 92 (19) , 8999-9003
- https://doi.org/10.1073/pnas.92.19.8999
Abstract
Monoclonal antibodies penetrate bulky tumors poorly after intravenous administration, in part because of specific binding to the target antigen. Experiments presented here demonstrate an analogous phenomenon in micrometastases; poor antibody penetration, attributable to a "binding-site barrier" phenomenon, can be seen in guinea pig micrometastases as small as 300 microns in diameter. Increasing the dose of antibody can partially overcome this limitation, but at a cost in specificity.Keywords
This publication has 37 references indexed in Scilit:
- Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convectionPublished by Elsevier ,2004
- Cancer Cell Invasion and MetastasisScientific American, 1992
- Localization by whole-body autoradiography of intact and fragmented radiolabeled antibodies in a metastatic human colonic cancer modelInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1992
- The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: An autoradiographic studyCancer Immunology, Immunotherapy, 1991
- Transport of fluid and macromolecules in tumorsMicrovascular Research, 1991
- Localization of monoclonal antibody auai and its F(ab')2 fragments in human tumour xenografts: An autoradiographic and immunohistochemical studyInternational Journal of Cancer, 1988
- The Pharmacology of Monoclonal AntibodiesaAnnals of the New York Academy of Sciences, 1987
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981
- Factor VIII related antigen as an endothelial cell marker in benign and malignant diseasesVirchows Archiv, 1981
- Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific ActivityNature, 1962